MedTrace Logo

Circular RNA and Chemerin in Breast Cancer Patient

NCT05771337 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-03-16

No results posted yet for this study

Summary

This study aimed to evaluate the role of serum chemerin as a biomarker of breast cancer.

and To investigate the diagnostic value of hsa\_circ\_0001785 (Circ-ELP3) and hsa\_circ\_100219 (Circ-FAF1) in serum samples of breast cancer patients to find out whether these circRNAs can utilize as a diagnostic and prognostic biomarker for human breast cancer assessment and make Correlation between serum chemerin levels , serum Circ-FAF1 , serum CircELP3 and classical tumor markers (CEA + CA15-3).

andTo elucidate if there is a difference between metastatic and non-metastatic cases as regard serum chemerin levels, serum Circ-FAF1 or Circ-ELP3.

Conditions

Interventions

DIAGNOSTIC_TEST

blood sample

blood sample

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2025-10-31
Completion
2025-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05771337 on ClinicalTrials.gov